

Contact Information

BANTAM PHARMACEUTICAL
(704) 460-5330
www.bantampharma.com
mluther@bantampharma.com

Leadership Team

Mike Luther, PhD, MBA
Chief Executive Officer
Matt Kostura, PhD,
Chief Scientific Officer
Alan Cooper, PhD,
Head, Chemistry
Meghan Reynolds,
Administrative Officer

Board of Directors

Mike Luther
Lionel Goldfrank
Victor Keen
John Reid
W. James Tozer Jr.

Key Advisors

Briggs Morrison, MD, Managing
Partner MPM Capital, CEO
Syndax, Inc.
Mike Patane, PhD, Chief
Scientific Officer, Mitobridge
Jedd Levine, MD, MBA
EVP Clinical Affairs, Oncology
Partners
Pam Cohen, MD, former Chief
Medical Officer at Blueprint
Medicines, Novartis
Rainer Fuchs, PhD, former CIO
Harvard Medical School; Biogen
& GSK R&D;
George Mulligan, PhD, VP
Translational Medicine
Mitobridge
Mark Manfredi, PhD
CSO Kyn Therapeutics, EIR Atlas
Ventures

Industry

Pharmaceuticals, Oncology
(Cancer metabolism, KRAS
mutated solid tumors /lymphoid
cancers)

Company Resources

Extensive patent estate and FTO
Owned IP promises protection
through 2037

Type of Financing Sought

\$5,000,000



BANTAM PHARMACEUTICAL is developing small molecule oncology therapeutics with a novel mechanism of action that modulate key elements of cancer cell metabolism critical for cancer development and growth. Bantam's orally available lead molecule, BTM-3528, targets a subset of solid tumors and hematologic cancers encompassing a \$10 billion oncology market opportunity. With \$10 million in funding raised to date, Bantam Pharmaceutical is seeking partners and investors as it rapidly advances BTM-3528 towards pivotal Phase I clinical trials.

COMPANY STRUCTURE AND MANAGEMENT: Bantam operates as a virtual company in a highly cost and capital efficient manner. The Bantam management team has deep experience in oncology biopharma drug discovery and development including science, operations, and business development. Bantam's scientific advisory board is comprised of prominent industry leaders with strong oncology drug development experience and leadership roles in early stage as well as global pharmaceutical companies.

BANTAM SCIENCE AND PIPELINE: Using a structure-based medicinal chemistry approach, Bantam has identified a unique set of compounds that reduce tumor cell growth and survival in a diverse set of cancer cell types. The molecular action of the compounds are tumor specific, and the compounds have no demonstrable effect on normal cells. The compounds display exceptional *in vivo* activity in tumor xenograft models including potent activity against KRAS mutant solid tumors including, but not limited to, colorectal and lung cancers. In addition, rapid tumor regression is observed in lymphoid xenografts. The lead compound of the series, BTM-3528, displays excellent ADMET properties and is well tolerated *in vivo*.

The mechanism by which BTM-3528 achieves its therapeutic effect is through the activation of the ATF4 mediated Integrated Stress Response (ISR) pathway. Activation of ISR is primed by dysregulation of essential metabolic pathways resulting in decreased intracellular glutathione, upregulation of the tumor suppressors ATF4 and p21 that ultimately leads to cell cycle arrest at G0/G1 and apoptosis. Based on biochemical, genomic, and cell line profiling, the mechanism of action for BTM-3528 is novel and distinct from other targeted therapeutics, including histone deacetylase, proteasome, and kinase inhibitors including the cyclin-dependent kinase inhibitors.

UNMET ONCOLOGY NEED AND MARKET OPPORTUNITY: Every year, more than a million and a half people are diagnosed with cancer in the US, and almost 1,700 people die from this disease per day. Though the survival rate as a whole has increased over the last decades, progress in therapeutic approaches has been incredibly variable, and for certain types of cancers such as lung, colorectal, and pancreatic cancers, advances have been incrementally modest and unsatisfactory. Bantam Pharmaceutical is committed to developing therapeutics to address these key unmet needs in cancer with the following areas of focus:

Diffuse Large B-Cell Lymphoma (DLBCL): Diffuse Large B-Cell Lymphoma is the most common form of non-Hodgkin's lymphoma and the current standard of care, chemo-immunotherapy (R-CHOP), provides durable remission and survival for only 50% of patients. Notably, BTM-3528 induces apoptosis in a wide array of DLBCL cell lines including ABC and GCB subtypes and those characterized by Myc and Bcl-2 genomic alterations ("double-hit" lymphomas). BTM-3528 also induces rapid and sustained tumor regression in *in vivo* xenograft models of B-Cell lymphoma. BTM-3528 has the potential to provide an effective new therapeutic approach to the limited treatment options available for relapsed and refractory DLBCL with a market potential that exceeds \$1 billion annually.

Total External Capital Invested
\$10,000,00 (from Founders and Investors)

Professionals
Jerry Silverman, CPA, Silverman Neu, LLP
Bill Gross, Esq. Stearns, Weaver, Miller, Weissler, Aldhadeff & Sitterson, PA
Mike Rivard, TriUnity PLC
Shailesh Maingi, CEO Kineticos

Year Founded & Type of Entity
2015 Delaware LLC

Key Features
Bantam operates in a virtual company infrastructure with a strong management team that has executive experience and expertise in oncology drug development from start-ups to global bio-pharmaceuticals.

Demonstrated Proof of Concept *in-vivo studies* in KRAS mutated solid tumors as well as B-cell lymphomas. No significant adverse safety issues to date;

Initial studies published in Bioorganic and Medicinal Chemistry Letters, and AACR Proceedings.

IP promises patent protection through 2037; Patent application publication: WO2016196644A1

\$ 10 billion market potential; Currently finalizing candidate selection studies for IND enabling GLP toxicology studies

Ongoing collaborations with McGill, NCI/NeXT, Frederick National Laboratory for Cancer Research, and SUNY-Hunter

KRAS Mutant Solid Tumors: Based on preclinical *in vitro* and *in vivo* data, cancers with a KRAS mutation are more likely to respond to BTM-3528 than cancers without a KRAS mutation. KRAS is a frequent “driver” mutation of three of the four most lethal cancers including colorectal cancer, lung adenocarcinoma, and pancreatic adenocarcinoma. The KRAS oncology market represents a substantial unmet need for cancer patients and collectively encompasses a \$9 billion annual market potential.

INTELLECTUAL PROPERTY: Bantam has exclusive rights to BTM-3528 and associated chemical space for all applications. In addition, Bantam owns recently filed patent applications that feature additional claims related to the mechanism and all routes of administration. Claims in the first of the two more recently filed applications were published in December 2016 in the US, and the second application, a PCT application filed in November 2016 has entered national phase filings. These filings will support patent protection for BTM-3528 and any derivative products through 2037.

NEAR TERM MILESTONES AND PROGRESSION TO CLINIC: We are rapidly progressing BTM-3528 to the clinic and are seeking funds to finalize GLP-pre-clinical activities in preparation for clinical trials. IND enabling studies and Phase Ia/Ib clinical trials are planned.

KEY MILESTONES	
Candidate Selection	December 2017
Initiate IND enabling studies	January 2018
File IND	December 2018
Initiate Phase Ib studies	January 2019
Complete Phase Ib	October 2019

FUNDING STRATEGY AND USE OF PROCEEDS: Bantam has raised \$4 million in three investor rounds post purchase of the assets from bankruptcy court. The Company has achieved its stated milestones for each raise. Bantam is presently seeking to syndicate a single \$5 million round to: 1) initiate and complete CMC development, 2) progress BTM-3528 through IND-enabling studies and Phase Ia/Ib clinical studies, and 3) bring the Company to an exit/partnering event with a significant investor ROI.